O041 - PERSONALIZED NUTRITION AND GUT MICROBIOME MODULATION TO SUPPORT CANCER TREATMENT: INSIGHTS FROM COLORECTAL CANCER PATIENTS

O041

PERSONALIZED NUTRITION AND GUT MICROBIOME MODULATION TO SUPPORT CANCER TREATMENT: INSIGHTS FROM COLORECTAL CANCER PATIENTS

C. M. Stroia^1,*, M. Vrânceanu², T. Ghitea³, A. Pallag³

¹Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, ² Toxicology, “Iuliu Hațieganu” University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, ³Pharmacy, University of Oradea, Oradea, Romania

Rationale: The gut microbiome plays a crucial role in regulating immune responses and influencing the effectiveness of immunotherapy in colorectal cancer (CRC) patients. Dysbiosis impairs immune function, particularly in patients with defective mismatch repair (dMMR) and high microsatellite instability (MSI-H), compromising the effectiveness of immune checkpoint inhibitors (ICIs). Nutrigenetic and microbiome profiling presents a novel strategy to optimize immunotherapy outcomes.

Methods: A prospective cohort study enrolled 102 CRC patients (61 males, 41 females; mean age 54±10 years). Genetic profiling focused on IL-6, TNF-α, CRP, SOD2, GPX1, GSTT1, GSTM1, FADS1, FADS2, and VDR polymorphisms. Microbiome diversity was assessed using 16S rRNA sequencing. Patients were divided into two groups (n=51): standard care and personalized nutrition, which included prebiotics, probiotics, omega-3 fatty acids, polyphenols, and vitamin D. Clinical biomarkers (CRP, IL-6, vitamin D) and gut microbiome were evaluated at baseline, 3, 6, and 12 months.

Results: Enhanced microbiome diversity (+33.19%, p<0.01) and reduced dysbiosis from severe (72.51) to near eubiosis (47.38, a 27.59% reduction). Inflammatory markers were significantly reduced: CRP by 92% (p<0.001), IL-6 by 85% (p<0.001). Vitamin D levels increased by 239.34% (p<0.01). Beneficial bacteria: Akkermansia muciniphila (+253%) and Faecalibacterium prausnitzii (+131%), showed substantial growth. Patients on the genetic diet demonstrated better progression.

Conclusion: Integrating nutrigenetics and microbiome profiling in CRC management represents a promising approach to improving immunotherapy responses. By personalizing nutrition based on genetic and microbiome profiling, particularly for dMMR/MSI-H patients, this strategy has the potential to optimize immunotherapy efficacy and advance precision oncology.

Disclosure of Interest: None declared